Long-Term Multilineage Engraftment of NOD/SCID Recipients Transplanted In Utero
| . | % Donor Cells . | % Ly5.1 Donor Cells . | ||
|---|---|---|---|---|
| . | Total . | CD3 . | B220 . | Mac/Gr-1 . |
| PB | 49 ± 13 | 43 ± 12 | 36 ± 9 | 32 ± 8 |
| BM | 22 ± 13 | 25 ± 6 | 40 ± 10 | 28 ± 7 |
| Spleen | 68 ± 14 | 56 ± 8 | 40 ± 7 | 7 ± 4 |
| . | % Donor Cells . | % Ly5.1 Donor Cells . | ||
|---|---|---|---|---|
| . | Total . | CD3 . | B220 . | Mac/Gr-1 . |
| PB | 49 ± 13 | 43 ± 12 | 36 ± 9 | 32 ± 8 |
| BM | 22 ± 13 | 25 ± 6 | 40 ± 10 | 28 ± 7 |
| Spleen | 68 ± 14 | 56 ± 8 | 40 ± 7 | 7 ± 4 |
The PB, BM, and spleens of in utero recipients were evaluated for the presence of donor cells 6 months posttransplant. The percentage of donor cells refers to the percentage of total Ly5+ cells that express the donor marker Ly5.1. The percentage of total Ly5.1 donor cells that express a specific-lineage marker is also shown (N = 6, mean ± SEM).